{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:33:24Z","timestamp":1789601604441,"version":"build-2803163510"},"reference-count":68,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.brachy.2023.06.228","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T20:34:39Z","timestamp":1694291679000},"page":"697-708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Actinium-225 Targeted Agents: Where Are We Now?"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4388-5334","authenticated-orcid":false,"given":"Firas","family":"Mourtada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4341-8226","authenticated-orcid":false,"given":"Katsumi","family":"Tomiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sims-Mourtada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Mukai-Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3443-3800","authenticated-orcid":false,"given":"Takayuki","family":"Yagihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Namiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-2945","authenticated-orcid":false,"given":"Taro","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomio","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.brachy.2023.06.228_bib0001","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/pharmaceutics13010049","article-title":"Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications","volume":"13","author":"Nelson","year":"2020","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.brachy.2023.06.228_bib0002","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/ph8020321","article-title":"A critical review of alpha radionuclide therapy-how to deal with recoiling daughters?","volume":"8","author":"de Kruijff","year":"2015","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.brachy.2023.06.228_bib0003","first-page":"425","article-title":"Realizing clinical trials with astatine-211: the chemistry infrastructure","volume":"35","author":"Lindegren","year":"2020","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"10.1016\/j.brachy.2023.06.228_bib0004","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3390\/cells9051165","article-title":"Alpha Radiation as a Way to Target Heterochromatic and Gamma Radiation-Exposed Breast Cancer Cells","volume":"9","author":"Svetli\u010di\u010d","year":"2020","journal-title":"Cells"},{"issue":"21","key":"10.1016\/j.brachy.2023.06.228_bib0005","first-page":"6095","article-title":"An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer","volume":"60","author":"McDevitt","year":"2000","journal-title":"Cancer research"},{"issue":"5546","key":"10.1016\/j.brachy.2023.06.228_bib0006","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.1064126","article-title":"Tumor therapy with targeted atomic nanogenerators","volume":"294","author":"McDevitt","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.brachy.2023.06.228_bib0007","unstructured":"Sonzogni A, Nudat Shu B. \u201c2.8 (Nuclear Structure and Decay Data). 2020.\u201d Available online: Nndc.bnl.gov (accessed on 8 September 2020)."},{"issue":"2","key":"10.1016\/j.brachy.2023.06.228_bib0008","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11523-018-0550-9","article-title":"Alpha-emitters and targeted alpha therapy in oncology: from basic science to clinical investigations","volume":"13","author":"Makvandi","year":"2018","journal-title":"Target Oncol"},{"issue":"3","key":"10.1016\/j.brachy.2023.06.228_bib0009","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1874471011666180502104524","article-title":"An overview of targeted alpha therapy with (225)actinium and (213)bismuth","volume":"11","author":"Morgenstern","year":"2018","journal-title":"Curr Radiopharm"},{"issue":"10","key":"10.1016\/j.brachy.2023.06.228_bib0010","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1007\/s00259-019-04401-9","article-title":"(225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.228_bib0011","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","article-title":"(225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.brachy.2023.06.228_bib0012","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2967\/jnumed.116.186338","article-title":"\u03b1-Emitters for radiotherapy: from basic radiochemistry to clinical studies-part 1","volume":"59","author":"Poty","year":"2018","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.brachy.2023.06.228_bib0013","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2967\/jnumed.117.204651","article-title":"\u03b1-Emitters for radiotherapy: from basic radiochemistry to clinical studies-part 2","volume":"59","author":"Poty","year":"2018","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.228_bib0014","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2967\/jnumed.121.262687","article-title":"Harnessing \u03b1-Emitting radionuclides for therapy: radiolabeling method review","volume":"63","author":"Yang","year":"2022","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.brachy.2023.06.228_bib0015","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.apradiso.2008.11.012","article-title":"Cyclotron and linac production of Ac-225","volume":"67","author":"Melville","year":"2009","journal-title":"Appl Radiat Isot"},{"issue":"3","key":"10.1016\/j.brachy.2023.06.228_bib0016","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/1874471011666180418141357","article-title":"The production of Ac-225","volume":"11","author":"Engle","year":"2018","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.brachy.2023.06.228_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.apradiso.2021.109676","article-title":"Transport model predictions of (225)Ac production cross sections via energetic p, d and alpha irradiation of (232)Th targets","volume":"172","author":"Burahmah","year":"2021","journal-title":"Appl Radiat Isot"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.228_bib0018","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40658-021-00410-6","article-title":"Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis","volume":"8","author":"Sgouros","year":"2021","journal-title":"EJNMMI Phys"},{"issue":"5","key":"10.1016\/j.brachy.2023.06.228_bib0019","first-page":"355","article-title":"Radiopharmaceutical quality control considerations for accelerator-produced actinium therapies","volume":"37","author":"Abou","year":"2022","journal-title":"Cancer Biother Radiopharm"},{"issue":"6","key":"10.1016\/j.brachy.2023.06.228_bib0020","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/pr10061215","article-title":"Research and development for cyclotron production of 225Ac from 226Ra: the challenges in a country lacking natural resources for medical applications","volume":"10","author":"Higashi","year":"2022","journal-title":"Processes"},{"key":"10.1016\/j.brachy.2023.06.228_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.apradiso.2021.109693","article-title":"Measurement of (227)Ac impurity in (225)Ac using decay energy spectroscopy","volume":"172","author":"Tollefson","year":"2021","journal-title":"Appl Radiat Isot"},{"issue":"3","key":"10.1016\/j.brachy.2023.06.228_bib0022","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/1874471011666180423120707","article-title":"In vivo evaluation of free and chelated accelerator-produced actinium- 225: radiation dosimetry and toxicity results","volume":"11","author":"Jiang","year":"2018","journal-title":"Curr Radiopharm"},{"issue":"20","key":"10.1016\/j.brachy.2023.06.228_bib0023","doi-asserted-by":"crossref","first-page":"9721","DOI":"10.7150\/thno.63860","article-title":"Practical considerations for quantitative clinical SPECT\/CT imaging of alpha particle emitting radioisotopes","volume":"11","author":"Benabdallah","year":"2021","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.brachy.2023.06.228_bib0024","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1007\/s00259-020-05024-1","article-title":"Image-based dosimetry for (225)Ac-PSMA-I&T therapy using quantitative SPECT","volume":"48","author":"Gosewisch","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"18","key":"10.1016\/j.brachy.2023.06.228_bib0025","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ac8b5f","article-title":"SPECT imaging of(226)Ac as a theranostic isotope for(225)Ac radiopharmaceutical development","volume":"67","author":"Koniar","year":"2022","journal-title":"Phys Med Biol"},{"issue":"10","key":"10.1016\/j.brachy.2023.06.228_bib0026","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.2967\/jnumed.110.077578","article-title":"The alpha-camera: a quantitative digital autoradiography technique using a charge-coupled device for ex vivo high-resolution bioimaging of alpha-particles","volume":"51","author":"Back","year":"2010","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.brachy.2023.06.228_bib0027","first-page":"487","article-title":"Quantification of activity by alpha-camera imaging and small-scale dosimetry within ovarian carcinoma micrometastases treated with targeted alpha therapy","volume":"56","author":"Chouin","year":"2012","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.brachy.2023.06.228_bib0028","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.2967\/jnumed.115.162388","article-title":"Alpha imaging confirmed efficient targeting of CD45-positive cells after 211At-radioimmunotherapy for hematopoietic cell transplantation","volume":"56","author":"Frost","year":"2015","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.brachy.2023.06.228_bib0029","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1118\/1.4921997","article-title":"Quantitative single-particle digital autoradiography with alpha-particle emitters for targeted radionuclide therapy using the iQID camera","volume":"42","author":"Miller","year":"2015","journal-title":"Med Phys"},{"issue":"3","key":"10.1016\/j.brachy.2023.06.228_bib0030","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2967\/jnumed.108.056036","article-title":"MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry: standardization of nomenclature","volume":"50","author":"Bolch","year":"2009","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.brachy.2023.06.228_bib0031","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.108.058651","article-title":"MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.228_bib0032","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13550-020-0614-6","article-title":"Accuracy in dosimetry of diagnostic agents: impact of the number of source tissues used in whole organ S value-based calculations","volume":"10","author":"Josefsson","year":"2020","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.228_bib0033","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00259-021-05583-x","article-title":"Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box","volume":"49","author":"Sgouros","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.brachy.2023.06.228_bib0034","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1667\/RR15081.1","article-title":"Modeling cell and tumor-metastasis dosimetry with the particle and heavy ion transport code system (PHITS) software for targeted alpha-particle radionuclide therapy","volume":"190","author":"Lee","year":"2018","journal-title":"Radiat Res"},{"issue":"3","key":"10.1016\/j.brachy.2023.06.228_bib0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12194-021-00628-0","article-title":"Medical application of particle and heavy ion transport code system PHITS","volume":"14","author":"Furuta","year":"2021","journal-title":"Radiol Phys Technol"},{"issue":"6","key":"10.1016\/j.brachy.2023.06.228_bib0036","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.brachy.2023.06.228_bib0037","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1053\/j.semnuclmed.2008.05.009","article-title":"Radiation dosimetry and exposure in nuclear medicine","volume":"38","author":"Stabin","year":"2008","journal-title":"Semin Nucl Med"},{"issue":"4","key":"10.1016\/j.brachy.2023.06.228_bib0038","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ijrobp.2020.08.026","article-title":"Toward Individualized voxel-level dosimetry for radiopharmaceutical therapy","volume":"109","author":"Xiao","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.brachy.2023.06.228_bib0039","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/1874471011104030261","article-title":"Modelling and dosimetry for alpha-particle therapy","volume":"4","author":"Sgouros","year":"2011","journal-title":"Curr Radiopharm"},{"issue":"3","key":"10.1016\/j.brachy.2023.06.228_bib0040","first-page":"235","article-title":"Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors","volume":"15","author":"Kennel","year":"2000","journal-title":"Cancer Biother Radiopharm"},{"issue":"3","key":"10.1016\/j.brachy.2023.06.228_bib0041","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1088\/0031-9155\/56\/3\/012","article-title":"Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody","volume":"56","author":"Schwartz","year":"2011","journal-title":"Phys Med Biol"},{"issue":"4","key":"10.1016\/j.brachy.2023.06.228_bib0042","first-page":"174","article-title":"Study of bone surface absorbed dose in treatment of bone metastases via selected radiopharmaceuticals: using MCNP4C code and available experimental data","volume":"30","author":"Bagheri","year":"2015","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.brachy.2023.06.228_bib0043","article-title":"International Commission on Radiation Units and Measurements report 96. Bethesda","author":"Sgouros","year":"2021","journal-title":"Dosim Guided Radiopharm Ther"},{"issue":"15","key":"10.1016\/j.brachy.2023.06.228_bib0044","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1021\/jm990141f","article-title":"Improved in vivo stability of actinium-225 macrocyclic complexes","volume":"42","author":"Deal","year":"1999","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.brachy.2023.06.228_bib0045","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s12350-019-01752-6","article-title":"(68)Ga-DOTA chelate, a novel imaging agent for assessment of myocardial perfusion and infarction detection in a rodent model","volume":"27","author":"Autio","year":"2020","journal-title":"J Nucl Cardiol"},{"issue":"11","key":"10.1016\/j.brachy.2023.06.228_bib0046","first-page":"1488","article-title":"Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region","volume":"24","author":"Mohtavinejad","year":"2021","journal-title":"Iran J Basic Med Sci"},{"issue":"15","key":"10.1016\/j.brachy.2023.06.228_bib0047","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.3390\/cancers13153904","article-title":"PSMA theranostics: Science and practice","volume":"13","author":"Mokoala","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.brachy.2023.06.228_bib0048","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.3390\/jcm11123311","article-title":"Ga-68-PSMA-11 PET\/CT in Patients with Biochemical Recurrence of Prostate Cancer after Primary Treatment with Curative Intent-Impact of Delayed Imaging","volume":"11","author":"Kunikowska","year":"2022","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.brachy.2023.06.228_bib0049","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.brachy.2023.06.228_bib0050","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3390\/pharmaceutics13050715","article-title":"Development of [(225)Ac]Ac-PSMA-I&T for targeted alpha therapy according to GMP guidelines for treatment of mCRPC","volume":"13","author":"Hooijman","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.brachy.2023.06.228_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101450","article-title":"Advances in PSMA theranostics","volume":"22","author":"Jeitner","year":"2022","journal-title":"Transl Oncol"},{"issue":"5","key":"10.1016\/j.brachy.2023.06.228_bib0052","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.117.203539","article-title":"Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control","volume":"59","author":"Kratochwil","year":"2018","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.brachy.2023.06.228_bib0053","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3390\/molecules25071743","article-title":"Targeted radionuclide therapy of prostate cancer-from basic research to clinical perspectives","volume":"25","author":"Czerwinska","year":"2020","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.brachy.2023.06.228_bib0054","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4274\/mirt.08760","article-title":"Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: stability, bio-distribution and dosimetry","volume":"26","author":"Kabasakal","year":"2017","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"3","key":"10.1016\/j.brachy.2023.06.228_bib0055","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.brachy.2023.06.228_bib0056","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2967\/jnumed.118.214379","article-title":"Salivary gland toxicity of PSMA radioligand therapy: relevance and preventive strategies","volume":"59","author":"Langbein","year":"2018","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.brachy.2023.06.228_bib0057","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s00259-020-05023-2","article-title":"Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC","volume":"48","author":"Ilhan","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.brachy.2023.06.228_bib0058","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.120.251017","article-title":"First clinical results for PSMA-targeted \u03b1-therapy using (225)Ac-PSMA-I&T in advanced-mCRPC Patients","volume":"62","author":"Zacherl","year":"2021","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.228_bib0059","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2967\/jnumed.116.178095","article-title":"Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET\/CT on clinical management in patients with neuroendocrine tumors","volume":"58","author":"Panagiotidis","year":"2017","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.brachy.2023.06.228_bib0060","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","article-title":"68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors","volume":"52","author":"Poeppel","year":"2011","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.brachy.2023.06.228_bib0061","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00259-019-04439-9","article-title":"Prognostic significance of somatostatin receptor heterogeneity in progressive neuroendocrine tumor treated with Lu-177 DOTATOC or Lu-177 DOTATATE","volume":"47","author":"Graf","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"S1","key":"10.1016\/j.brachy.2023.06.228_bib0062","first-page":"S36","article-title":"Ac-225-DOTATOC: dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors","volume":"42","author":"Kratochwil","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.brachy.2023.06.228_bib0063","doi-asserted-by":"crossref","first-page":"462","DOI":"10.7861\/clinmedicine.17-5-462","article-title":"Molecular radiotheranostics for neuroendocrine tumours","volume":"17","author":"Navalkissoor","year":"2017","journal-title":"Clin Med (Lond)"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.228_bib0064","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13550-018-0443-z","article-title":"Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review","volume":"8","author":"Huizing","year":"2018","journal-title":"EJNMMI Res"},{"issue":"1091","key":"10.1016\/j.brachy.2023.06.228_bib0065","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180108","article-title":"Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy","volume":"91","author":"Pencharz","year":"2018","journal-title":"Br J Radiol"},{"issue":"22","key":"10.1016\/j.brachy.2023.06.228_bib0066","doi-asserted-by":"crossref","first-page":"6088","DOI":"10.7150\/thno.30357","article-title":"The theranostic promise for neuroendocrine tumors in the late 2010s: where do we stand, where do we go?","volume":"8","author":"Werner","year":"2018","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.brachy.2023.06.228_bib0067","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4103\/wjnm.wjnm_160_20","article-title":"Targeted alpha-particle therapy in neuroendocrine neoplasms: a systematic review","volume":"20","author":"Koh","year":"2021","journal-title":"World J Nucl Med"},{"issue":"6","key":"10.1016\/j.brachy.2023.06.228_bib0068","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/cas.15327","article-title":"Neuroendocrine tumor theranostics","volume":"113","author":"Ichikawa","year":"2022","journal-title":"Cancer Sci"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472123015945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472123015945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:18:50Z","timestamp":1761531530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472123015945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1538472123015945"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2023.06.228","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actinium-225 Targeted Agents: Where Are We Now?","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2023.06.228","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}